These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 2284572)

  • 1. Fusidic acid treatment of HIV infection: no significant effect in a pilot trial.
    Hørding M; Christensen KC; Faber V
    Scand J Infect Dis; 1990; 22(6):649-52. PubMed ID: 2284572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind trial of bestatin in HIV-positive patients.
    Hørding M; Gøtzsche PC; Dalh Christensen L; Bygbjerg IC; Faber V
    Biomed Pharmacother; 1990; 44(9):475-8. PubMed ID: 2081275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo and in vitro efficacy of fusidic acid in HIV infection.
    Famularo G; De Simone C; Tzantzoglou S; Trinchieri V; Moretti S; Tonietti G
    Ann N Y Acad Sci; 1993 Jun; 685():341-3. PubMed ID: 7689807
    [No Abstract]   [Full Text] [Related]  

  • 4. Lack of immunomodulating effect of disulfiram on HIV positive patients.
    Hørding M; Gøtzsche PC; Bygbjerg IC; Christensen LD; Faber V
    Int J Immunopharmacol; 1990; 12(2):145-7. PubMed ID: 2184133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HIV replication in vitro by fusidic acid.
    Faber V; Dalgleish AG; Newell A; Malkovsky M
    Lancet; 1987 Oct; 2(8563):827-8. PubMed ID: 2443777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fusidic acid on the hepatic cytochrome P450 enzyme system.
    Reimann G; Barthel B; Rockstroh JK; Spatz D; Brockmeyer NH
    Int J Clin Pharmacol Ther; 1999 Nov; 37(11):562-6. PubMed ID: 10584978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusidic acid in dermatology: an updated review.
    Schöfer H; Simonsen L
    Eur J Dermatol; 2010; 20(1):6-15. PubMed ID: 20007058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections.
    Gilbert M
    J Am Acad Dermatol; 1989 Jun; 20(6):1083-7. PubMed ID: 2502567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of bile salts and of fusidic acid on HIV-1 infection of cultured cells.
    Lloyd G; Atkinson T; Sutton PM
    Lancet; 1988 Jun; 1(8600):1418-21. PubMed ID: 2898581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.
    Wannamethee SG; Sirivichayakul S; Phillips AN; Ubolyam S; Ruxrungtham K; Hanvanich M; Phanuphak P
    Int J Epidemiol; 1998 Apr; 27(2):289-95. PubMed ID: 9602412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Silver-based Gel Compared With Fusidic Acid Cream in Topical Treatment Following Trichloroacetic Acid Facial Skin Peeling: A Pilot Study.
    Landau G; Gabario S; Menashe S; Saadon H; Heller L
    Wounds; 2018 Dec; 30(12):363-366. PubMed ID: 30260319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men.
    Burack JH; Barrett DC; Stall RD; Chesney MA; Ekstrand ML; Coates TJ
    JAMA; 1993 Dec; 270(21):2568-73. PubMed ID: 7901433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of vancomycin, teicoplanin and fusidic acid as prophylactic agents in prevention of vascular graft infection: an experimental study in rat.
    Yasim A; Gul M; Atahan E; Ciragil P; Aral M; Ergun Y
    Eur J Vasc Endovasc Surg; 2006 Mar; 31(3):274-9. PubMed ID: 16360328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of fusidic acid on Tanzanian patients with AIDS.
    Jørgensen AF; Mwakyusa D; Cegielski P; Gøtzsche P; Hørding M; Lallinger G; Mbaga I; Pallangyo K; Richter C; Shao J
    AIDS; 1990 Oct; 4(10):1037-8. PubMed ID: 2261122
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen.
    Anderson DJ; O'Brien TR; Politch JA; Martinez A; Seage GR; Padian N; Horsburgh CR; Mayer KH
    JAMA; 1992 May; 267(20):2769-74. PubMed ID: 1349654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study between teicoplanin alone and flucloxacillin, plus or minus fusidic acid, in the treatment of serious infections caused by methicillin-susceptible gram-positive bacteria.
    Mehtar S; Drabu Y; Wilson AP; Grüneberg RN
    Chemotherapy; 1995; 41(5):412-9. PubMed ID: 8521744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of disease progression in HIV-infected homosexual men with CD4+ cells < 200 x 10(6)/l but free of AIDS-defining clinical disease.
    Keet IP; Krol A; Koot M; Roos MT; de Wolf F; Miedema F; Coutinho RA
    AIDS; 1994 Nov; 8(11):1577-83. PubMed ID: 7848594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
    Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
    Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive evaluation of the immune risk phenotype in successfully treated HIV-infected individuals.
    Ndumbi P; Gilbert L; Tsoukas CM
    PLoS One; 2015; 10(2):e0117039. PubMed ID: 25647167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the antiretroviral activity of a new polyherbal drug (Immu-25) in patients with HIV infection.
    Usha PR; Naidu MU; Raju YS
    Drugs R D; 2003; 4(2):103-9. PubMed ID: 12718564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.